No abstract

No abstract

In the recent years, the current technology enables only the molten iron base alloys, sprayed on the aluminum alloy engine block thus it can function as a cylinder bore. However, the machinability performance of plasma spray coated cylinder bore in boring process is poor because of severe tool wear compared with the previous cast iron cylinder bore. This paper deals with the results obtained at boring process of plasma sprayed iron base alloys coating to clarify the root cause of tool wear. Preliminary fine boring and turning experiments are conducted on the plasma sprayed cylinder bore, and tool wear, tool failure modes and cutting force were also investigated. The result shows plasma spray coated cylinder bore recorded larger cutting force than the cast iron cylinder bore. Also, this work shows that abrasive effect by the hard oxide particles on the cross-sectioned of machined layer is superior when fine boring plasma spraying iron base alloys coating.

1-Trimethylacetyl derivatives 9 and 10 of 3-(2-butenyl)indole 7 and 3-(3-methyl-2-butenyl)indole 8 were regioselectively cyclized at the 4-position of indole nucleus.In the biosynthesis of ergot alkaloids 3, a prenyl group is first introduced at 4-position of tryptophan as shown in the scheme(l).Although many attempts to introduce a such substituent at the position of indole nucleus have been studied for a long time, no successful method has been reported except a few cases(2,3).

16068 Background: For optimal debulked mullerian cancer (MC), the Intraperitoneal (IP) therapy has become the effective modality of chemotherapy to obtain better prognosis. We have reported KCOG9811study: IP CDDP + Paclitaxel (PTX) intravenous (IV) 2 cycles followed by 3 cycles of usual PTX-Carboplatin (abstr.1970, ASCO2002). And we have also reported the feasibility study and satisfactory response rate of the weekly IP-PTX with IV Carboplatin therapy (IP-PIVC, abstr. 5120, ASCO2005). Objectives: We have conducted two types of IP therapy for optimal debulked MC to improve the progression free survival (PFS) and overall survival (OS). Here are the prognosis and recurrent fashion after these IP therapies. Methods: Twenty patients (pts) with optimal debulked ovarian cancer were enrolled for KCOG9811, and eleven pts with optimal debulked MC newly/recurrent diagnosed disease were enrolled for IP-PIVC. The regimen of each therapy consisted of as follows: KCOG9811:50mg/ m2 of CDDP was administered via IP port at operation, after 2 weeks (wks) of operation, PTX was administered at a dose of 175mg/ m2IV for 3hrs on day 1, CDDP was administered at 75mg/ m2IP on day 2, every 3wks for 2 cycles, followed by PTX 175mg/ m2 IV and Carboplatin AUC5 IV on day1 every 3wks for 3 cycles. The IP-PIVC therapy consisted of IP-PTX, on days 1, 8, 15 at a dose of 45 mg/m2 (3pts) and 60 mg/m2(8pts). Carboplatin was administered monthly at a dose of AUC 5 on day 1 only. 2–6 cycles were performed. Results: The mean observation time was 72.6 months (m) and 32.6m for KCOG9811 and IP-PIVC, respectively. As for the median PFS was 1308+ days and 678+ days, and the median OS was 2180+ days and 978+ days, respectively. The five years survival rate showed 59.3% on KCOG9811, and the three years survival rate showed 75.8% on IP-PIVC. As for recurrent fashion, liver metastases and proximal lymphnodes metastases, and retroperitoneal metastases were detected. Few cases recurred Intraperitoneal lesion with small ascites Conclusions: There are some differences in the recurrent fashion of IP treatment from that of IV treatment. IP treatment prevented ascitic recurrence. Further improvement of chemotherapy is necessary for liver metastasis and proximal lymphnodes. [Table: see text]